EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Woman Who Lost Husband to Male Breast Cancer Goes on Road... September 16, 2021 Improving Cancer Immunotherapy: Overcoming the Problem of ‘Exhausted’ T Cells July 18, 2019 Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban February 7, 2022 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 Load more HOT NEWS Weekend in New England Precision drug slows progression of advanced breast cancer Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor... New study identifies how obesity may increase the risk of developing...
